Pulmonx (LUNG) EBIT (2019 - 2025)

Pulmonx (LUNG) has reported EBIT for 7 consecutive years, with -$14.4 million the latest figure, recorded in Q3 2025.

• On a quarterly basis, EBIT fell 1.87% year-over-year to -$14.4 million in Q3 2025; TTM through Sep 2025 was -$57.2 million, a 1.77% increase from a year earlier, with the FY2024 full-year figure at -$57.7 million, up 6.83% from the prior year.
• EBIT was -$14.4 million for Q3 2025 at Pulmonx, up from -$14.8 million in the prior quarter.
• Over five years, EBIT peaked at -$9.8 million in Q3 2021 and troughed at -$16.4 million in Q2 2023.
• A 5-year average of -$14.2 million and a median of -$14.4 million in 2022 frame the typical range for EBIT.
• Across the five-year window, EBIT sank 104.69% in 2021 and gained 11.37% in 2024, its largest moves.
• Over 5 years, EBIT stood at -$12.4 million in 2021, then slipped by 18.28% to -$14.6 million in 2022, then rose by 4.84% to -$13.9 million in 2023, then increased by 3.61% to -$13.4 million in 2024, then declined by 7.27% to -$14.4 million in 2025.
• The last three EBIT figures came in at -$14.4 million (Q3 2025), -$14.8 million (Q2 2025), and -$14.6 million (Q1 2025), per Business Quant data.